We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
TIRX | Tian Ruixiang Holdings Ltd | 0.90 | 0.41525 | 85.66% | 3,480,059 |
TRVN | Trevena Inc | 0.5402 | 0.1382 | 34.38% | 2,687,322 |
ALRN | Aileron Therapeutics Inc | 4.99 | 0.74 | 17.41% | 4,569 |
WKSP | Worksport Ltd | 0.4399 | 0.0646 | 17.21% | 7,365 |
GROM | Grom Social Enterprises Inc | 0.7299 | 0.0968 | 15.29% | 2,755 |
VRAX | Virax Biolabs Group Ltd | 0.783 | 0.0951 | 13.82% | 200 |
GRTX | Galera Therapeutics Inc | 0.224 | 0.0256 | 12.90% | 482,646 |
CNTB | Connect Biopharma Holdings Inc | 1.75 | 0.20 | 12.90% | 383 |
SINT | SiNtx Technologies Inc | 0.0418 | 0.0045 | 12.06% | 14,902,639 |
POAI | Predictive Oncology Inc | 1.45 | 0.1513 | 11.65% | 246 |
LEXX | Lexaria Bioscience Corporation | 2.59 | 0.25 | 10.68% | 277 |
RADNOR, Pa., April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
LONDON, April 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) on April 27-30, 2024, in Barcelona, Spain.
The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a Biologics License Application (BLA), and certain tax credits.
HONG KONG, April 17, 2024 /PRNewswire/ -- ICZOOM Group Inc. (Nasdaq: IZM) (the "Company" or "ICZOOM"), announced today that it voluntarily requested a withdrawal of a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (File No.333-275708, the "Registration Statement") and accordingly cancelled the proposed public offering pursuant to the Registration Statement .
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
IGPK | Integrated Cannabis Solutions Inc | 314 | |
FNMA | Fannie Mae | 98 | |
SPZI | SPOOZ Inc | 194 | |
4 | AVXL | Anavex Life Sciences Corp | 60 |
5 | AMRN | Amarin Corp Plc | 48 |
6 | CYDY | Cytodyn Inc | 39 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 61,630.71 | -2,213.25 | -3.47% | 1.21T | 7,150,920,844 |
ETH | Ethereum | 3,008.10 | -76.72 | -2.49% | 357.3B | 3,060,912,000 |
USDT | Tether USD | 0.9999 | -0.0001 | -0.01% | 97.84B | 443,173,026 |
BNB | Binance Coin | 539.42 | 1.28 | 0.24% | 84.48B | 467,946,618 |
SOL | Solana | 136.70 | 0.330 | 0.24% | 58.87B | 2,142,431,839 |
STETH | stETH | 2,989.35 | -74.92 | -2.45% | 29.1B | 16,345,765 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 1,227,656,387 |
XRP | Ripple | 0.4966 | -0.0001 | -0.02% | 26.78B | 444,042,553 |
TONCOIN | Wrapped TON Coin | 6.15 | -0.207399 | -3.26% | 21.02B | 224,211,449 |
DOGE | Dogecoin | 0.14998 | -0.00607 | -3.89% | 21.02B | 639,490,361 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions